TNDM logo

Tandem Diabetes Care Stock Price

Symbol: NasdaqGM:TNDMMarket Cap: US$1.0bCategory: Healthcare

TNDM Share Price Performance

US$15.40
-25.39 (-62.25%)
50.5% undervalued intrinsic discount
US$31.10
Fair Value
US$15.40
-25.39 (-62.25%)
50.5% undervalued intrinsic discount
US$31.10
Fair Value
Price US$15.40
AnalystConsensusTarget US$31.10

TNDM Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$31.10 50.5% undervalued intrinsic discount

FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative

Recent TNDM News & Updates

No updates

Tandem Diabetes Care, Inc. Key Details

US$983.0m

Revenue

US$469.6m

Cost of Revenue

US$513.3m

Gross Profit

US$697.2m

Other Expenses

-US$183.9m

Earnings

Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 06, 2025
Earnings per share (EPS)
-2.76
Gross Margin
52.22%
Net Profit Margin
-18.71%
Debt/Equity Ratio
228.2%

Tandem Diabetes Care, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About TNDM

Founded
2006
Employees
2650
CEO
John Sheridan
WebsiteView website
www.tandemdiabetes.com

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 10.7%
  • 1 Year: 17.5%
  • Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading